Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned

Published: Friday, May 16, 2014
Last Updated: Friday, May 16, 2014
Bookmark and Share
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.

Novasep has announced that its EUR 4 million (USD 5.5m) investment to expand its highly potent active pharmaceutical ingredients (HPAPI) manufacturing capabilities at its Le Mans facility in France has reached fruition. The plant extension has been fully qualified and is now being used to scale up validation of a commercial ADC (antibody drug conjugate) payload.

HPAPI, the majority of which are used in anti-cancer therapies, must be produced under very strict regulatory conditions to protect any API substance from cross contamination and protect operators from the highly active properties that are intrinsic to these products.

Contract Manufacturing Organizations (CMOs) increasingly need to upgrade their facilities with higher containment capabilities. Ensuring supply chain continuity is also important to meet the rising demand in the pharmaceutical industry for ADCs.

“We are pleased to see the Le Mans facility commissioned, fully operational and successfully FDA audited,” said Thierry Van Nieuwenhove president of the Synthesis Business unit at Novasep. “There is a high demand from the pharmaceutical industry for CMOs to manufacture potent molecules for use in drugs that improve efficacy and reduce side effects. Novasep has the development and manufacturing capacity, level of specialization and experience to safely address the needs of this market.”

Novasep’s Le Mans plant, notable for producing highly potent cytotoxic pharmaceutical ingredients (APIs) and registered advanced intermediates, recently passed US FDA (Federal Drug Administration) inspection.

The Le Mans production facility combines chemical and purification capabilities to manufacture potent and extremely potent ADC payloads at commercial scale with an OEL (occupational exposure limit) lower than 30 ng/m3 at multi-kg scale per batch.

On top of the classical chemical features in installed confined areas, the production suite can perform cryogenic chemistry at minus 60 degrees Celsius in hastelloy reactors.

The purification suite is equipped with a Prochrom® industrial High-Performance Liquid Chromatography (HPLC) system, which Novasep in Pompey designed and built.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep, Triclinic Labs Partner
Partnership will enable Novasep to offer early-stage solid-state chemistry services in North America.
Thursday, September 15, 2016
Novasep Appoints Dr. François D’Hooge as Bioconjugation Unit Manager
Dr. D’Hooge will manage Novasep’s new antibody drug conjugates (ADC) production facility in Le Mans, France, currently undergoing completion.
Tuesday, September 06, 2016
Novasep, GTP Technology Join Forces
Partnership offers biotech firms full CDMO services at all development stages from gene to end product.
Tuesday, March 22, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Novasep’s European Custom Manufacturing Passes FDA Inspection
Two successful FDA inspections assure customers of Novasep’s strict compliance with US pharmaceutical processing standards.
Thursday, October 24, 2013
Novasep Appoints Christian Thiry as Chief Financial Officer
CFO appointment is a key milestone in Novasep’s senior management recruitment program.
Thursday, August 29, 2013
Novasep Appoints President and CEO
Novasep announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013.
Thursday, June 27, 2013
Novasep Appoints Fine Chemicals Market Director
Company strengthens its position by appointing Udo Steinhauer.
Thursday, June 06, 2013
Novasep Invests to Build World's Largest Chromatography Plant for the Pharmaceutical Industry
The investment of €30 million allows Novasep to build the largest chromatography plant for the production of a large volume commercial API’s in Mourenx, France.
Wednesday, October 10, 2012
Changes to Novasep Governance
Roger-Marc Nicoud becomes non-executive chairman of the board.
Wednesday, October 03, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!